This also applies to the tumour pro–angiogenic mechanisms, which are modulated by 43% overlapping drug effects, with a lower PD1 inhibitor specific contribution in this case (10%; Figure 2, Supplementary Table 4). Here, PDCD1 is linked to neoplasm.